MASSDEVICE ON CALL — Despite warnings from advisory panels and pressure from consumer groups, the FDA announced that no recall would be issued for silicone breast implants.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
The Advanced Medical Technology Assn. or AdvaMed spent more than $366,000 during the second quarter and $417,000 so far this year to lobby Congress in favor of the medical device industry.
Q2 spending represents a 4 percent dip from the same time last year, when the group spent just over $379,000.
The Advanced Medical Technology Assn. or AdvaMed, is moving from the land of policy to the land of production.
The national council for the medical device industry officially kicked off its AdvaMed 2012 conference at a reception at Fenway Park. The council will bring its annual conference to the Bay State next October. The move will undoubtedly bring the conference closer to the action.
The medical device industry is keeping the pressure on Congress to push for a vote to repeal the medical device tax, a 2.3 percent levy on U.S. sales of medical equipment, which was contained in last year’s landmark health care reform law.
More than 400 medical device companies, industry councils and other stakeholders signed a letter addressed to leaders in both the House of Representatives and Senate, asking legislators to repeal the tax outright.
As Congress considers cuts in health care spending and the FDA prepares to reauthorize users fees for medical devices, industry lobby AdvaMed issued a report finding that national medical device prices and spending have barely budged over the last two decades.
Device and diagnostic prices have increased at an average annual rate of 1.0 percent compared to national inflation at 2.8 percent, according to the report.
The medi-tech industry is trying to stay ahead of medical device fees to assure some products are not taxed twice under the new excise tax on industry contained in the health care bill.
As expected, the Advanced Medical Technology Assn. submitted another round of public comments to the IRS in an effort to mitigate the chance of some medical device companies being taxed twice under the new 2.3 percent excise tax, which is slated to go into effect in 2013.
The FDA doesn’t appear to be buying the two year compromise on user fees that the medical device industry is floating in lieu of a full reauthorization of the fees med tech companies pay to the watchdog agency.
In a Medical Device User Fee Reauthorization or MDUFMA III stakeholder meeting with members of patient advocacy groups, FDA officials said that the medical device industry had not provided “a substantive response” to the agency’s request for more funding to increase its overall headcount.
The medical device industry is asking the FDA to take a couple more years to meet goals it says the watchdog agency has failed to meet before it agrees on reauthorizing user fees for another go-around.
In the Medical Device User Fee Reauthorization or MDUFMA III negotiation meeting, which was held early in June, a group representing the medical device industry said the agency has “not yet achieved” some of the qualitative and quantitative goals set when the user fee program was reauthorized in 2007.
The Medical device industry is stepping up the pressure on congress in its call for a more consistent regulatory environment at the FDA.
The Advanced Medical Technology Association, or AdvaMed, flew 20 medical device CEO’s into Washington to “urge Congress to help preserve the industry’s competitiveness and global leadership in the development of new medical devices and diagnostics.”
Two Republican senators are calling for the reauthorization of the FDA user fee act as a catalyst for changes at the agency.
In a letter addressed to the various councils representing the life sciences industry, Sens. Richard Burr (R-NC) and Tom Coburn (R-OK) wrote that “reauthorization of the U.S. Food and Drug Administration user fee agreements provides an important opportunity to address the root causes of the threats to our nation’s leadership in medical innovation.”